AskAt 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
grapiprant (RQ-00000007) / AskAt, Ikena Oncology, Maruishi Pharma
NCT05265052: 3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain

Not yet recruiting
2
177
NA
3D1002 (50 mg)(Phase IIa), 3D1002 (100 mg)(Phase IIa), 3D1002 (150 mg)(Phase IIa), 3D1002 monotherapy (Phase IIb), OxyContin monotherapy (Phase IIb), 3D1002 + OxyContin (Phase IIb)
3D Medicines
Cancer Pain
12/25
12/25
NCT05041101: Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer

Terminated
1/2
6
US
Eribulin Mesylate, B1939 Mesylate, E7389, ER-086526, Halaven, Halichondrin B Analog, Grapiprant, AAT-007, AT-001, CJ 023,423, CJ-023,423, CJ023,423, RQ-00000007, RQ-07
M.D. Anderson Cancer Center
Breast Inflammatory Carcinoma, Recurrent Breast Inflammatory Carcinoma, Stage IV Breast Inflammatory Carcinoma
09/24
09/24
KEYNOTE-878, NCT03658772: Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer

Completed
1b
54
US
grapiprant, ARYS-007, IK-007, grapiprant and pembrolizumab, ARYS-007, MK3475, KEYNOTE-878
Arrys Therapeutics, Merck Sharp & Dohme LLC
Microsatellite Stable Colorectal Cancer
03/23
03/23
ChiCTR1800015060: phase I clinical study evaluated the safety, tolerability, and pharmacokinetic characteristics of RMX1002 in healthy Chinese adult subjects

Recruiting
1
32
 
placebo
Zhongshan Hospital Affiliated to Fudan University; Zhongshan Hospital Affiliated to Fudan University, Fully self-raised
Arthritis, pain, familial adenomatous polyposis
 
 
ChiCTR1900026031: A Single Arm, Open-label, Dose Escalation and Expansion Study for RMX1002 in the Treatment of Advanced Solid Tumor Patients

Recruiting
1
50
 
Divide into 7 groups and treat respectively ;Two appropriate dose
Beijing Cancer Hospital; Beijing Cancer Hospital, Ningbo NewBay Medical Technology Ltd., Co.
Advanced solid tumor
 
 
OCT461201 / Oxford Cannabinoid Techno, AskAt
NCT06398925: Single Ascending Oral Dose Study to Investigate the Effects of OCT461201 in Healthy Volunteers

Completed
1
32
Europe
OCT461201 50 mg, OCT461201 100 mg, OCT461201 150 mg, OCT461201 450 mg, Placebo
Oxford Cannabinoid Technologies Holdings PLC, Simbec-Orion Group
Healthy
09/23
09/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
grapiprant (RQ-00000007) / AskAt, Ikena Oncology, Maruishi Pharma
NCT05265052: 3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain

Not yet recruiting
2
177
NA
3D1002 (50 mg)(Phase IIa), 3D1002 (100 mg)(Phase IIa), 3D1002 (150 mg)(Phase IIa), 3D1002 monotherapy (Phase IIb), OxyContin monotherapy (Phase IIb), 3D1002 + OxyContin (Phase IIb)
3D Medicines
Cancer Pain
12/25
12/25
NCT05041101: Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer

Terminated
1/2
6
US
Eribulin Mesylate, B1939 Mesylate, E7389, ER-086526, Halaven, Halichondrin B Analog, Grapiprant, AAT-007, AT-001, CJ 023,423, CJ-023,423, CJ023,423, RQ-00000007, RQ-07
M.D. Anderson Cancer Center
Breast Inflammatory Carcinoma, Recurrent Breast Inflammatory Carcinoma, Stage IV Breast Inflammatory Carcinoma
09/24
09/24
KEYNOTE-878, NCT03658772: Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer

Completed
1b
54
US
grapiprant, ARYS-007, IK-007, grapiprant and pembrolizumab, ARYS-007, MK3475, KEYNOTE-878
Arrys Therapeutics, Merck Sharp & Dohme LLC
Microsatellite Stable Colorectal Cancer
03/23
03/23
ChiCTR1800015060: phase I clinical study evaluated the safety, tolerability, and pharmacokinetic characteristics of RMX1002 in healthy Chinese adult subjects

Recruiting
1
32
 
placebo
Zhongshan Hospital Affiliated to Fudan University; Zhongshan Hospital Affiliated to Fudan University, Fully self-raised
Arthritis, pain, familial adenomatous polyposis
 
 
ChiCTR1900026031: A Single Arm, Open-label, Dose Escalation and Expansion Study for RMX1002 in the Treatment of Advanced Solid Tumor Patients

Recruiting
1
50
 
Divide into 7 groups and treat respectively ;Two appropriate dose
Beijing Cancer Hospital; Beijing Cancer Hospital, Ningbo NewBay Medical Technology Ltd., Co.
Advanced solid tumor
 
 
OCT461201 / Oxford Cannabinoid Techno, AskAt
NCT06398925: Single Ascending Oral Dose Study to Investigate the Effects of OCT461201 in Healthy Volunteers

Completed
1
32
Europe
OCT461201 50 mg, OCT461201 100 mg, OCT461201 150 mg, OCT461201 450 mg, Placebo
Oxford Cannabinoid Technologies Holdings PLC, Simbec-Orion Group
Healthy
09/23
09/23

Download Options